HAE vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HAE exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating a robust financial trajectory. While the stock is currently trading above its Graham Number ($39.87), it remains significantly undervalued relative to its growth-based intrinsic value ($107.08) and a PEG ratio of 0.92. Despite a bearish technical trend and slight revenue contraction (-2.70%), the company demonstrates exceptional operational efficiency with 28.4% earnings growth and a consistent track record of beating EPS estimates. The divergence between strong internal fundamentals and poor price performance suggests a value opportunity.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
HAE vs MRK: Head-to-Head Comparison
This page compares Haemonetics Corporation (HAE) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.